gamma-glutamylcysteine | 686-58-8

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: gamma-glutamylcysteine
• 英文别名: γ-glutamyl cysteine；γ-glutamyl-cysteine；γ-glutamylcysteine；γ-GC；γ-L-glutamyl-L-cysteine；gamma-L-glutamyl-L-cysteine；2-Amino-5-[(1-carboxy-2-sulfanylethyl)amino]-5-oxopentanoic acid
• CAS: 686-58-8
• 化学式: C₈H₁₄N₂O₅S
• 分子量: 250.276
• InChiKey: RITKHVBHSGLULN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.8
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  131
• 氢给体数：
  5
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  gamma-glutamylcysteine 在 3,3,3-膦三基三丙酸 、 recombinant ovothiol A from Erwinia tasmaniensis 、 iron(II) sulfate 、 sodium chloride 、 D,L-histidine 作用下， 生成 di-γ-glutamyl-cystine
  参考文献：
  名称：

  Identification and Characterization of the First Ovothiol Biosynthetic Enzyme

  摘要：

  Ovothiols are histidine-derived thiols that were first isolated from marine invertebrates. We have identified a 5-histidylcysteine sulfoxide synthase (OvoA) as the first ovothiol biosynthetic enzyme and characterized OvoAs from Erwinia tasmaniensis and Trypanosoma cruzi. Homologous enzymes are encoded in more than 80 genomes ranging from proteobacteria to animalia.

  DOI：

  10.1021/ja109378e

文献信息

• PEPTIDOMIMETIC GLUTATHIONE ANALOGS
  申请人：UNIVERSITEIT LEIDEN

  公开号：US20040063640A1

  公开（公告）日：2004-04-01

  The invention relates to peptidomimetic compounds with formula 1 wherein Z=CH 2 and Y=CH 2 , or Z=O and Y=C═C), which are novel analogs of glutathion and are inhibitors of glutathione S-tansferase, in particular of GST P1-1. Such inhibition has beneficial effects in therapy against cancer. In particular compounds in which R 3 is H, R 4 is benzyl and R 5 is phenyl are stable towards &ggr;GT activity and are selective for GST P1-1.

  本发明涉及具有公式1的肽模拟化合物，其中Z＝CH2，Y＝CH2，或者Z＝O和Y＝C＝CH），它们是谷胱甘肽的新颖类似物，并且是谷胱甘肽S转移酶的抑制剂，特别是GST P1-1的抑制剂。这种抑制作用在癌症治疗中具有有益效果。 特别是当R3为H，R4为苄基，R5为苯基时，这些化合物对γGT活性稳定，并且对GST P1-1具有选择性。
• [EN] METHODS FOR THE TREATMENT OF CYSTEAMINE SENSITIVE DISORDERS<br/>[FR] MÉTHODES DE TRAITEMENT DES TROUBLES SENSIBLES À LA CYSTÉAMINE
  申请人：THIOGENESIS THERAPEUTICS INC

  公开号：WO2019060634A1

  公开（公告）日：2019-03-28

  The invention features methods for the treatment of cystinosis and other cysteamine sensitive disorders in a subject including administration of a disulfide convertible to cysteamine in vivo. The methods can include the separate administration of a reducing agent to the subject to increase the bioavailablity and extend the plasma pharmacokinetic profile of the cysteamine produced following administration of the disulfide. The methods permit sustained cysteamine plasma concentrations in a subject.

  这项发明涉及治疗囊性氨基酸病和其他对半胱氨酸敏感的疾病的方法，包括在体内给予可转化为半胱氨酸的二硫化物。该方法可以包括向受试者单独给予还原剂，以增加半胱氨酸在给予二硫化物后产生的生物利用度，并延长血浆药代动力学特性。该方法允许受试者体内维持持续的半胱氨酸血浆浓度。
• Compositions for potentiating glutatthione
  申请人：Chiba Tomohiro

  公开号：US20060257351A1

  公开（公告）日：2006-11-16

  A composition for potentiating glutathione, which contains at least one member selected from the group consisting of 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, a plant containing 2-(3,4-dihydroxyphenyl)ethanol or a glycoside thereof, an extract of said plant, a hydrolysate of said plant, and a hydrolysate of the extract of said plant (excluding Olea europaea and an extract thereof), and which further contains at least one member selected from among an S-containing compound that is a supply source of cysteine, a protein that contains cysteine and/or cystine, a yeast that contains cysteine and/or cystine, and a vitamin.

  一种用于增强谷胱甘肽作用的组合物，包含至少从以下组合中选择的一种成员：2-(3,4-二羟基苯基)乙醇或其糖苷，含有2-(3,4-二羟基苯基)乙醇或其糖苷的植物，该植物的提取物，该植物的水解产物，以及该植物提取物的水解产物（不包括欧洲橄榄和其提取物），并且进一步包含至少从以下成员中选择的一种：供应半胱氨酸的含硫化合物，含有半胱氨酸和/或半胱氨酸的蛋白质，含有半胱氨酸和/或半胱氨酸的酵母，以及维生素。
• [EN] PREVENTION AND TREATMENT OF OCULAR CONDITIONS<br/>[FR] PRÉVENTION ET TRAITEMENT D'ÉTATS OCULAIRES
  申请人：ASCENDIS PHARMA AS

  公开号：WO2013053856A1

  公开（公告）日：2013-04-18

  The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions.

  本发明涉及含有水凝胶连接的前药的药物组合物，用于治疗、预防和/或诊断眼部疾病的条件以及包括所述药物组合物的眼科器械。
• PREVENTION AND TREATMENT OF OCULAR CONDITIONS
  申请人：Ascendis Pharma Growth Disorders Division A/S

  公开号：US20170112939A1

  公开（公告）日：2017-04-27

  The present invention relates to pharmaceutical compositions comprising hydrogel-linked prodrug for use in the treatment, prevention and/or diagnosis a condition of the eye and ophthalmic devices comprising said pharmaceutical compositions.

  本发明涉及含有水凝胶连接的前药的药物组合物，用于治疗、预防和/或诊断眼部疾病，并且包括该药物组合物的眼科设备。